[Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China].
OBJECTIVE
To collect background information on drug-resistant HIV-1 strains in various regions before the start of nation-wide antiretroviral therapy in China.


METHODS
Twenty percent of the 2,000 blood samples from antiretroviral therapy naive patients collected for the 2nd national HIV molecular epidemiology survey (NHMES) in 2002 were randomly sampled for this study. The entire protease gene and 20-230 amino acids of the reverse transcriptase gene were amplified by PCR from provirus DNA and sequenced. The results were analyzed with HIV db-Drug Resistance Algorithm and genotypic resistance mutations were determined to particular anti-HIV drugs.


RESULTS
Totally 164 protease gene sequences and 138 reverse transcriptase gene sequences were obtained from patients; 0.61% of 164 sequences displayed primary resistance mutations in the protease gene, whereas 99.39% carried 1 or more secondary mutations. Genotypic resistance to at least one nucleoside reverse transcriptase inhibitors (NRTI) was present in 5.80%,and resistance to at least one non-nucleo side reverse transcriptase inhibitors (NNRTI) was present in 1.45% of samples.


CONCLUSIONS
The prevalence of genotypic drug resistance is very low in drug-naive HIV infected patients from 21 provinces of China tested in this study. Laboratories participated in the NHMES have organized a network to provide drug resistance monitoring service in the current nation-wide antiviral treatment program in China.
Si
Xue-feng
XF
National Center for AIDS/STD Prevention and Control, China Center for Disease Prevention and Control, Beijing 100050, China.
Huang
Hai-long
HL
Wei
Min
M
Guan
Qi
Q
Song
Yan-hui
YH
Ma
Peng-fei
PF
Quan
Yu
Y
Xing
Hui
H
Shao
Yi-ming
YM
D019380:Anti-HIV Agents / Q000627:therapeutic use; D002681:China / Q000453:epidemiology; D024882:Drug Resistance, Viral; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D018571:Sentinel Surveillance
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase; D016333:HIV Protease